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http://dx.doi.org/10.1016/j.jmoldx.2012.05.001CorrectionIn the article entitled, “Multiplex Mutation Screening by
Mass Spectrometry: Evaluation of 820 Cases from a Per-
sonalized Cancer Medicine Registry” (Volume 13, pages
504–513 of the September 2011 issue of The Journal of
Molecular Diagnostics), the corresponding author’s dis-
closures were inadvertently omitted. The disclosures
should have read as follows:
CME Disclosure: CLC receives research support from
Novartis, serves as a consultant/advisory board member
418for Novartis and Sequenom, and is a member of the
speakers’ bureau for Novartis. None of the other authors
disclosed any relevant financial relationships.
Dr. Corless asserts, “These fees were no way related
to the work that we published, and my relationship with
Novartis had no impact on the care of patients who
consented to our Personalized Cancer Medicine
Registry, as it was only a registry and not a clinical
trial.”
